Moderna will spike another 25% from current levels after encouraging progress on coronavirus vaccine, Goldman says
Business Insider -


Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed "encouraging" results.

Moderna announced Monday that all 45 volunteers in the trial produced antibodies to protect against COVID-19 infection. Shares jumped as much as 39% on the news.

The new price target implies a 25% leap from Moderna's price at 12:25 p.m. ET.

Analyst Salveen Richter raised the vaccine's probability of success to 75% from 70%, and...

Read this story at


Related Articles